What it does
BPC-157 is a synthetic 15-amino-acid peptide derived from a fragment found in human gastric juice. The preclinical literature is large and consistent across rodent models of tendon, gut, vascular, and central nervous system injury — animals injected with BPC-157 heal faster, with reduced inflammation. Human evidence is limited to small case series and a handful of mechanistic measurements; there are no published Phase 2 or Phase 3 randomized trials in humans for any musculoskeletal or gastrointestinal indication. Community framing — particularly around tendon and post-injury recovery — runs far ahead of what's been demonstrated in people.
Used for
Dose
- Starting
- 250 mcg · 1–2× daily
- Common
- 375 mcg · 1–2× daily
- Upper
- 500 mcg · 1–2× daily
- When
- Split — morning + eveningShort half-life supports BID dosing for tissue repair — most published community protocols split AM and PM. For site-specific injection near an injury, timing is less load-bearing than for systemic dosing.
- How long
- 2 months on / 1 month off
- Site
- subcutaneous near injury site or systemic
- Food
- any
Need exact volumes? Open the peptide calculator →
⚠ Caution
- Active malignancy (theoretical concern given growth-factor upregulation in animal models)
- Pregnancy and breastfeeding (no human safety data)
- Hypersensitivity to peptide excipients
- Long-term continuous use beyond ~30 days lacks human safety data
Medications & conditions
- BPC-157 with anticoagulant — additive bleeding riskUser is taking an anticoagulant. BPC-157 has demonstrated antiplatelet and angiogenic effects in animal models, which can additively increase bleeding risk when stacked with prescription anticoagulants. No human trials have characterized the magnitude of this effect at therapeutic peptide doses.
- BPC-157 contraindicated in active oncologyBPC-157 has documented angiogenic and cell-proliferation effects in animal models. These mechanisms are not desirable in the context of active malignancy and have not been studied alongside chemotherapy or radiation. Discontinue and discuss with the oncology team before considering peptide therapy in this setting.
- BPC-157 with SSRI/SNRI — clinician review recommendedUser is taking a serotonergic antidepressant. BPC-157 modulates dopaminergic and serotonergic pathways in animal models; the clinical significance in humans on therapeutic SSRI/SNRI doses is unknown. This is a precautionary clinician-review flag rather than evidence of harm.
- BPC-157 with corticosteroid — reduced tissue-repair effectUser is taking a corticosteroid. Corticosteroids are catabolic and impair the collagen synthesis, angiogenesis, and cellular recruitment pathways that BPC-157 relies on for tissue repair. The magnitude of BPC-157's regenerative benefit may be substantially reduced in the presence of high-dose steroid therapy.
Will it work for me?
Establish a baseline (2–3 readings over 1–2 weeks before starting), then track at consistent intervals.
- Tier 2 — Human observationalhs-CRP↓· 6–12 weeksInflammation overlay, not a direct action marker.
- Tier 3 — Animal / in vitroRegion-specific function score (DASH / KOOS / ODI)↑· 6–12 weeksSelf-administered functional tracking is the practical default.
- Tier 3 — Animal / in vitroPain scale (VAS / NPRS)↓· 2–4 weeks
Often stacked with
- GHK-Cu — BPC-157 drives VEGF-mediated angiogenesis at injury sites while GHK-Cu remodels extracellular matrix and suppresses inflammation — complementary tissue-repair arms.
- KPV — BPC-157 drives mucosal healing via VEGF/NO pathways; KPV suppresses NF-κB-driven intestinal inflammation via PepT1 — mechanistically complementary for IBD-adjacent stacks.
- TB-500 — BPC-157 promotes angiogenesis at injury sites; TB-500 (Tβ4 fragment) enhances actin-driven cell migration — parallel tissue-repair pathways that do not duplicate each other.
Your stack
Track this peptide in your protocol — dose, schedule, vials on hand, refill projection. Stays in your browser; no account needed.
Add to my stack